A Phase 1 interventional study of BI 754091 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients with dose-limiting toxicities (DLTs) in patients with selected advanced solid malignancies. Safety and tolerability will be evaluated by monitoring the occurrence of adverse events (AEs), serious AEs (SAE), and laboratory parameter abnormalities, as well as changes to vital signs.
Secondary objectives are the determination of the PK profile of BI 754091 after single and multiple doses of BI 754091, and the preliminary assessment of antitumour activity.
In the dose-expansion part of the trial, the main objectives are to further assess the safety, efficacy, PK profile, and biomarkers of BI 754091 in tumours with specific tumour types and/or genetic mutations at the RP2D.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 110 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase Ia (dose-escalation)
Phase Ib (dose expansion)
Females of willing to use adequate measures from the time of screening until 6 months after trial discontinuation, who are not or will not be breast feeding, and agree to have pregnancy tests prior to the start of dosing and at regular visits during the trial. Females not of childbearing potential must have evidence of such by fulfilling one of the following criteria at screening:
Exclusion criteria:
Inadequate organ function or bone marrow reserve as demonstrated by the following laboratory values:
Any of the following cardiac criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose.
Drug: BI 754091
Medium dose.
Drug: BI 754091
High dose.
Drug: BI 754091
Patients with solid tumours including NSCLC, bladder cancer, melanoma, gastric cancer, ovarian cancer, triple-negative breast cancer, and renal-cell cancer
Drug: BI 754091
Patients with tumours with high TMB excluding those with high microsatellite instability (MSI-high)
Drug: BI 754091
Patients with refractory squamous cell cervical, anal, and skin tumours.
Drug: BI 754091
Patients with recurrent human papillomavirus (HPV)-positive, or HPV-negative, vaginal or vulvar squamous cell carcinoma (VSCC)
Drug: BI 754091
Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks)
Number of participants experiencing dose-limiting toxicities (DLTs) graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0 observed in the first cycle (3 weeks) in order to meet the objective of assessment of the maximum tolerated dose (MTD) of ezabenlimab.
Time frame: Up to 3 weeks.
Phase Ib Dose Expansion: Number of Participants With Dose-limiting Toxicities (DLTs) During the Entire Treatment Period
Phase Ib dose expansion: Number of participants with dose-limiting toxicities (DLTs) during the entire treatment period
Time frame: From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.
Phase Ib Dose Expansion: Confirmed Objective Response (OR), Defined as the Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 as Assessed by the Investigator
Confirmed objective Response (OR), defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 assessed by the Investigator, where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.
Time frame: From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.
Phase Ia Dose Escalation: Confirmed Objective Response According to RECIST v.1.1 as Assessed by the Investigator
Confirmed OR, defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.
Time frame: From the first administration of BI 754091 until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent, up to 511 days.
Phase Ia Dose Escalation: Maximum Measured Concentration (Cmax) of Ezabenlimab in Plasma
Maximum measured concentration (Cmax) of ezabenlimab in plasma after single or multiple dose administration of ezabenlimab. Results for cycle 1 and cycle 2 are reported.
Time frame: 5 minutes prior to BI 754091 infusion start and 0.5, 1, 1.5, 2, 4, 7, 24, 72, 168 and 336 hours after start of BI 754091 infusion.
Phase Ia Dose Escalation: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504)
Area under the Concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) after single and multiple dose administrations of ezabenlimab. Results for cycle 1 and cycle 2 are reported.
Time frame: 5 minutes prior to BI 754091 infusion start and 0.5, 1, 1.5, 2, 4, 7, 24, 72, 168, 336 and 504 hours after start of BI 754091 infusion.
Phase Ia Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) From the Start of Treatment Until End of Treatment
Number of participants experiencing dose-limiting toxicities (DLTs), graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0, from the start of treatment until end of treatment (in all cycles) as assessed approximately every 3 weeks.
Time frame: From first infusion of study treatment until the last infusion of study treatment plus 30 days, up to 511 days.
Phase Ib Dose Expansion: Confirmed Progression-free Survival (PFS) Defined From Date of Start of Ezabenlimab to the Date of Disease Progression or Death, Whichever Was Earlier, According to RECIST v1.1 as Assessed by the Investigator
Confirmed Progression-free survival (PFS) defined from date of start administration of BI 754091 to the date of disease progression according to RECIST v1.1 as assessed by the Investigator or death from any cause, whichever is earlier. PFS according to RECIST v1.1: For patients with 'event' as outcome for PFS: \- PFS \[days\] = date of outcome - date of first treatment administration + 1 For patients with 'censored' as outcome for PFS: \- PFS (censored) \[days\] = date of outcome - date of first treatment administration+ 1 Median progression free survival time in months is reported.
Time frame: From first BI 754091 infusion until disease progression or death, whichever is earlier up to 1668 days.
Phase Ib Dose Expansion: Percentage of Participants With Adverse Events (AEs)
Percentage of participants with adverse events (AEs)
Time frame: From first infusion of study treatment until end of study treatment plus 30 days, up to 1668 days.
Phase Ib Dose Expansion: Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participants with serious adverse events (SAEs).
Time frame: From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.
Phase Ib Dose Expansion: Percentage of Participants With Clinically Relevant Abnormalities in Laboratory Evaluations
Percentage of participants with clinically relevant abnormalities in laboratory evaluations is reported by the percentage of participants with liver enzyme elevations. Abbreviations: ALT: Alanine aminotransferase ALP: Alkaline Phosphatase AST: Aspartate aminotransferase ULN: Upper limit of normal \*: Tbili elevation must be within +/- 30 days of ALT and/or AST elevation
Time frame: From first infusion of study treatment until end of study treatment plus 30 days, up to 1668 days.
An open-label, multicentre, phase 1 trial in patients with advanced solid tumours. Phase Ia dose escalation part consists of 3 cohorts (80, 240 and 400 mg ezabenlimab) to determine the maximum tolerated dose, followed by Phase Ib dose expansion with 4 cohorts to further evaluate safety, pharmacokinetics and efficacy of ezabenlimab.
| Milestone | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 30 | 27 | 31 | 13 |
| Completed | 0 | 0 | 0 | 0 | 3 | 4 | 0 |
| Not completed | 3 | 3 | 3 | 30 | 24 | 27 | 13 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 3 | 2 |
| Withdrew: Progressive disease | 3 | 3 | 3 | 27 | 20 | 22 | 9 |
| Withdrew: Missed 2 cycles of treatment due to covid-19 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Patient decision | 0 | 0 | 0 | 1 | 3 | 1 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Number of participants experiencing dose-limiting toxicities (DLTs) graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0 observed in the first cycle (3 weeks) in order to meet the objective of assessment of the maximum tolerated dose (MTD) of ezabenlimab.
| Participants | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab |
|---|---|---|---|
| Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks) | 0 | 0 | 0 |
Phase Ib dose expansion: Number of participants with dose-limiting toxicities (DLTs) during the entire treatment period
| Participants | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|
| Phase Ib Dose Expansion: Number of Participants With Dose-limiting Toxicities (DLTs) During the Entire Treatment Period | 0 | 0 | 0 | 0 |
Confirmed objective Response (OR), defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 assessed by the Investigator, where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.
| Participants | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|
| Phase Ib Dose Expansion: Confirmed Objective Response (OR), Defined as the Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 as Assessed by the Investigator | 4 | 4 | 6 | 2 |
Confirmed OR, defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.
| Participants | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab |
|---|---|---|---|
| Phase Ia Dose Escalation: Confirmed Objective Response According to RECIST v.1.1 as Assessed by the Investigator | 0 | 1 | 0 |
Maximum measured concentration (Cmax) of ezabenlimab in plasma after single or multiple dose administration of ezabenlimab. Results for cycle 1 and cycle 2 are reported.
| Microgram/Milliliter | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab |
|---|---|---|---|
| Cycle 1 | 25.3 ± 32.7 | 73.7 ± 9.93 | 128 ± 27.1 |
| Cycle 2 | 33.3 ± 23.7 | 96.4 ± 18.3 | 144 ± 21.9 |
Area under the Concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) after single and multiple dose administrations of ezabenlimab. Results for cycle 1 and cycle 2 are reported.
| Microgram*hours/milliliter | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab |
|---|---|---|---|
| Cycle 1 | 4640 ± 28.0 | 14300 ± 19.6 | 22000 ± 31.9 |
| Cycle 2 | 6790 ± 18.1 | 18800 ± 21.5 | 28500 ± 37.1 |
Number of participants experiencing dose-limiting toxicities (DLTs), graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0, from the start of treatment until end of treatment (in all cycles) as assessed approximately every 3 weeks.
| Participants | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab |
|---|---|---|---|
| Phase Ia Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) From the Start of Treatment Until End of Treatment | 0 | 0 | 0 |
Confirmed Progression-free survival (PFS) defined from date of start administration of BI 754091 to the date of disease progression according to RECIST v1.1 as assessed by the Investigator or death from any cause, whichever is earlier. PFS according to RECIST v1.1: For patients with 'event' as outcome for PFS: \- PFS \[days\] = date of outcome - date of first treatment administration + 1 For patients with 'censored' as outcome for PFS: \- PFS (censored) \[days\] = date of outcome - date of first treatment administration+ 1 Median progression free survival time in months is reported.
| Months | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|
| Phase Ib Dose Expansion: Confirmed Progression-free Survival (PFS) Defined From Date of Start of Ezabenlimab to the Date of Disease Progression or Death, Whichever Was Earlier, According to RECIST v1.1 as Assessed by the Investigator | 1.9 (1.2 to 3.3) | 2.7 (1.3 to NA) | 2.6 (1.4 to 6.1) | 4.2 (1.4 to 5.5) |
Percentage of participants with adverse events (AEs)
| Percentage of participants | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|
| Phase Ib Dose Expansion: Percentage of Participants With Adverse Events (AEs) | 96.7 | 96.3 | 96.8 | 100.0 |
Percentage of participants with serious adverse events (SAEs).
| Percentage of participants | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|
| Phase Ib Dose Expansion: Percentage of Participants With Serious Adverse Events (SAEs) | 33.3 | 25.9 | 48.4 | 46.2 |
Percentage of participants with clinically relevant abnormalities in laboratory evaluations is reported by the percentage of participants with liver enzyme elevations. Abbreviations: ALT: Alanine aminotransferase ALP: Alkaline Phosphatase AST: Aspartate aminotransferase ULN: Upper limit of normal \*: Tbili elevation must be within +/- 30 days of ALT and/or AST elevation
| Percentage of participants | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|
| Maximum ALT; >= 3x ULN and <5x ULN | 3.3 | 3.7 | 0.0 | 0.0 |
| Maximum AST; >= 3x ULN and <5x ULN | 0.0 | 11.1 | 0.0 | 7.7 |
| Maximum AST; >= 5x ULN and <10x ULN | 3.3 | 0.0 | 0.0 | 0.0 |
| Maximum Total Bilirubin; >=2x ULN | 0.0 | 11.1 | 3.2 | 0.0 |
| ALT and/or AST >= 3xULN and * total bilirubin >= 2xULN | 0.0 | 3.7 | 0.0 | 0.0 |
| Maximum ALP; >=3x ULN and <5x ULN | 3.3 | 11.1 | 3.2 | 0.0 |
| Maximum ALP; >=5x ULN and <10x ULN | 0.0 | 14.8 | 3.2 | 0.0 |
Collected over All-cause Mortality: From study start until end of study, up to 2444 days. Serious and other AEs: From treatment start until end of treatment, plus 30 days of residual effect period, up to 511 days for phase Ia dose escalation and up to 1668 days for phase Ib dose expansion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase Ia Dose Escalation: 80 mg Ezabenlimab | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase Ia Dose Escalation: 240 mg Ezabenlimab | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase Ia Dose Escalation: 400 mg Ezabenlimab | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | 16/30 (53.3%) | 10/30 (33.3%) | 27/30 (90%) |
| Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | 10/27 (37%) | 9/27 (33.3%) | 24/27 (88.9%) |
| Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | 17/31 (54.8%) | 16/31 (51.6%) | 30/31 (96.8%) |
| Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC | 9/13 (69.2%) | 6/13 (46.2%) | 13/13 (100%) |
| Event | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/3 | 1/3 | 1/3 | 0/30 | 0/27 | 0/31 | 0/13 |
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/30 | 0/27 | 2/31 | 0/13 |
| Arterial injuryInjury, poisoning and procedural complications | 1/3 | 0/3 | 0/3 | 0/30 | 0/27 | 0/31 | 0/13 |
| FistulaMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 1/3 | 0/30 | 0/27 | 0/31 | 0/13 |
| Foot amputationSurgical and medical procedures | 1/3 | 0/3 | 0/3 | 0/30 | 0/27 | 0/31 | 0/13 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 0/3 | 0/30 | 0/27 | 3/31 | 0/13 |
| SepsisInfections and infestations | 0/3 | 0/3 | 0/3 | 1/30 | 1/27 | 3/31 | 0/13 |
| Infusion site extravasationGeneral disorders | 0/3 | 0/3 | 0/3 | 0/30 | 0/27 | 0/31 | 1/13 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/3 | 0/30 | 0/27 | 0/31 | 1/13 |
| OsteomyelitisInfections and infestations | 0/3 | 0/3 | 0/3 | 0/30 | 0/27 | 0/31 | 1/13 |
| Event | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/3 | 1/3 | 2/3 | 9/30 | 5/27 | 9/31 | 8/13 |
| FatigueGeneral disorders | 1/3 | 1/3 | 2/3 | 12/30 | 6/27 | 16/31 | 5/13 |
| Weight decreasedInvestigations | 0/3 | 1/3 | 2/3 | 2/30 | 2/27 | 5/31 | 1/13 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 1/3 | 2/3 | 6/30 | 5/27 | 6/31 | 4/13 |
| HypokalaemiaMetabolism and nutrition disorders | 0/3 | 1/3 | 2/3 | 2/30 | 4/27 | 5/31 | 1/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/3 | 0/3 | 2/3 | 5/30 | 2/27 | 6/31 | 1/13 |
| InsomniaPsychiatric disorders | 2/3 | 0/3 | 0/3 | 0/30 | 1/27 | 7/31 | 2/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/3 | 2/3 | 0/3 | 6/30 | 1/27 | 8/31 | 3/13 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 2/30 | 9/27 | 7/31 | 5/13 |
| ConstipationGastrointestinal disorders | 1/3 | 1/3 | 1/3 | 4/30 | 3/27 | 6/31 | 5/13 |
Treated Set (TS): The TS included all participants who received at least 1 dose of ezabenlimab.
| Age, Continuous(Years) | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 57.3 ± 11.0 | 58.3 ± 23.8 | 54.7 ± 7.8 | 64.8 ± 12.6 | 65.0 ± 10.7 | 52.5 ± 13.0 | 63.5 ± 11.5 | 60.6 ± 13.2 |
| Sex: Female, Male(Participants) | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 25 | 16 | 27 | 13 | 84 |
| Male | 2 | 3 | 1 | 5 | 11 | 4 | 0 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 | 3 | 2 | 0 | 7 |
| Not Hispanic or Latino | 3 | 2 | 3 | 29 | 22 | 27 | 13 | 99 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Phase Ia Dose Escalation: 80 mg Ezabenlimab | Phase Ia Dose Escalation: 240 mg Ezabenlimab | Phase Ia Dose Escalation: 400 mg Ezabenlimab | Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours | Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB | Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin | Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 2 | 5 | 2 | 1 | 11 |
| White | 2 | 3 | 3 | 25 | 19 | 29 | 12 | 93 |
| More than one race | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing
Ran from Nov 2016 to primary completion in Apr 2021, 53 months.
Results were first posted in Jan 2026, 4 years 8 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 53 months is above that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezabenlimab